IRINOTECAN ACCORD 20mg / ml perfusive solution concentrate medication leaflet

L01CE02 irinotecan • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Topoisomerase 1 (TOP1) inhibitors

Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.

The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.

Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.

Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.

General data about IRINOTECAN ACCORD 20mg / ml

Substance: irinotecan

Date of last drug list: 01-06-2025

Commercial code: W65797003

Concentration: 20mg / ml

Pharmaceutical form: perfusive solution concentrate

Quantity: 1

Product type: generic

Price: 254.27 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 9233/2016/03

Shelf life: 3 years

Concentrations available for irinotecan

1.5mg/ml, 20mg/ml, 4.3mg/ml

Other substances similar to irinotecan

Compensation lists for IRINOTECAN ACCORD 20mg / ml ACCORD

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

254.27 RON

254.27 RON

0.00 RON